HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

J Randolph Hecht Selected Research

panitumumab (Vectibix)

9/2015Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
6/2015SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
7/2014PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
4/2010Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
2/2009A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
5/2008Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
9/2007Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
7/2007Panitumumab in colorectal cancer.
3/2007Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
11/2006Panitumumab in colon cancer: a review and summary of ongoing trials.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


J Randolph Hecht Research Topics

Disease

22Colorectal Neoplasms (Colorectal Cancer)
09/2015 - 04/2002
11Neoplasms (Cancer)
12/2015 - 02/2003
6Adenocarcinoma
07/2015 - 02/2003
4Disease Progression
06/2015 - 03/2007
4Carcinoma (Carcinomatosis)
12/2012 - 04/2002
3Neutropenia
06/2015 - 04/2010
3Diarrhea
06/2015 - 04/2002
3Colonic Neoplasms (Colon Cancer)
12/2012 - 11/2004
2Neoplasm Metastasis (Metastasis)
01/2015 - 02/2003
2Hypertension (High Blood Pressure)
12/2012 - 06/2005
2Pancreatic Neoplasms (Pancreatic Cancer)
02/2012 - 11/2004
2Infection
04/2010 - 02/2009
2Stomach Neoplasms (Stomach Cancer)
03/2010 - 05/2006
1Melanoma (Melanoma, Malignant)
12/2015
1Esophageal Neoplasms (Esophageal Cancer)
07/2015
1Hypokalemia
06/2015
1Hypotension (Low Blood Pressure)
06/2015
1Dehydration (Water Stress)
06/2015
1Sarcoma (Soft Tissue Sarcoma)
06/2015
1Anoxia (Hypoxia)
05/2011
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
03/2010
1Pulmonary Embolism
02/2009
1Renal Cell Carcinoma (Grawitz Tumor)
03/2008
1Fatigue
03/2008
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
02/2008
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2004
1Breast Neoplasms (Breast Cancer)
11/2004
1Pancreatitis
02/2003
1Sepsis (Septicemia)
02/2003

Drug/Important Bio-Agent (IBA)

12Fluorouracil (Carac)FDA LinkGeneric
06/2015 - 03/2003
11panitumumab (Vectibix)FDA Link
09/2015 - 01/2006
10irinotecan (Camptosar)FDA LinkGeneric
06/2015 - 04/2002
10bevacizumabFDA Link
06/2015 - 06/2005
10oxaliplatin (Eloxatin)FDA LinkGeneric
06/2015 - 09/2007
9Leucovorin (Folinic Acid)FDA Link
06/2015 - 06/2005
9Epidermal Growth Factor Receptor (EGF Receptor)IBA
06/2015 - 11/2006
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2015 - 06/2005
3capecitabine (Xeloda)FDA Link
10/2014 - 12/2012
3Phosphotransferases (Kinase)IBA
03/2010 - 11/2004
2Codon (Codons)IBA
09/2015 - 07/2014
2Epidermal Growth Factor (EGF)IBA
09/2015 - 07/2007
2cetuximab (Erbitux)FDA Link
09/2015 - 03/2015
2everolimusFDA Link
07/2015 - 03/2015
2AntibodiesIBA
06/2015 - 05/2006
2sunitinib (Sutent)FDA Link
01/2015 - 03/2008
2vatalanib (PTK787)IBA
05/2011 - 05/2011
2imatinib (Gleevec)FDA Link
03/2008 - 02/2008
2Cisplatin (Platino)FDA LinkGeneric
05/2006 - 04/2002
2ONYX015 (ONYX-015)IBA
04/2003 - 02/2003
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2015
1Monoclonal AntibodiesIBA
09/2015
1Biological Markers (Surrogate Marker)IBA
07/2015
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2015
1XELOXIBA
12/2012
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2011
1lactate dehydrogenase 5IBA
05/2011
1pegfilgrastim (Neulasta)FDA Link
04/2010
1trastuzumab (Herceptin)FDA Link
03/2010
1lapatinib (GW572016)FDA Link
03/2010
1erlotinib (CP 358,774)FDA Link
03/2010
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
03/2008
1tyrosine receptor (receptor, tyrosine)IBA
02/2008
1Antineoplastic Agents (Antineoplastics)IBA
09/2007
1GastrinsIBA
05/2006
1antigastrinIBA
05/2006
1HormonesIBA
05/2006
12- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA
11/2004
1PD 0325901IBA
11/2004
1Paclitaxel (Taxol)FDA LinkGeneric
09/2003
1DNA (Deoxyribonucleic Acid)IBA
04/2003
1Neutralizing AntibodiesIBA
04/2003
1Anti-Bacterial Agents (Antibiotics)IBA
02/2003
1Lipase (Acid Lipase)FDA Link
02/2003
1gemcitabineFDA Link
02/2003
1Amifostine (Ethyol)FDA LinkGeneric
04/2002

Therapy/Procedure

12Drug Therapy (Chemotherapy)
06/2015 - 04/2003
1Immunotherapy
12/2015
1Adjuvant Chemotherapy
12/2012
1Radiotherapy
02/2012
1Cutaneous Administration
02/2012
1Heterologous Transplantation (Xenotransplantation)
03/2010